Related references
Note: Only part of the references are listed.Epigenetic Therapies and Biomarkers in Breast Cancer
Lauren Julia Brown et al.
CANCERS (2022)
Decitabine potentiates efficacy of doxorubicin in a preclinical trastuzumab-resistant HER2-positive breast cancer models
Verona Buocikova et al.
BIOMEDICINE & PHARMACOTHERAPY (2022)
TET1 Isoforms Have Distinct Expression Pattern, Localization and Regulation in Breast Cancer
Mahmoud Alzahayqa et al.
FRONTIERS IN ONCOLOGY (2022)
Paradoxical whole genome DNA methylation dynamics of 5'aza-deoxycytidine in chronic low-dose exposure in mice
Mathia Colwell et al.
EPIGENETICS (2021)
Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network
Xiaorong Gu et al.
LEUKEMIA (2021)
Calcium signaling in cancer progression and therapy
Ling Wu et al.
FEBS JOURNAL (2021)
Ten-eleven translocation proteins (TETs): tumor suppressors or tumor enhancers?
Cuili Ma et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2021)
Combining epigenetic drugs with other therapies for solid tumours - past lessons and future promise
Daphne Morel et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Epigenetics in Breast Cancer Therapy-New Strategies and Future Nanomedicine Perspectives
Verona Buocikova et al.
CANCERS (2020)
DNMT Inhibitors Increase Methylation in the Cancer Genome
Anil K. Giri et al.
FRONTIERS IN PHARMACOLOGY (2019)
SOX5 promotes breast cancer proliferation and invasion by transactivation of EZH2
Chuntao Sun et al.
ONCOLOGY LETTERS (2019)
Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials
Yuan Cheng et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
Effects of 5-Aza-2-deoxycytidine (decitabine) on gene expression
Ratnam S. Seelan et al.
DRUG METABOLISM REVIEWS (2018)
DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine
Jia Yu et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Cytidine Deaminase Deficiency Reveals New Therapeutic Opportunities against Cancer
Hamza Mameri et al.
CLINICAL CANCER RESEARCH (2017)
ONGene: A literature-based database for human oncogenes
Yining Liu et al.
JOURNAL OF GENETICS AND GENOMICS (2017)
Gene-body hypermethylation controlled cryptic promoter and miR26A1-dependent EZH2 regulation of TET1 gene activity in chronic lymphocytic leukemia
Pradeep Kumar Kopparapu et al.
ONCOTARGET (2017)
Roles of Rap1 signaling in tumor cell migration and invasion
Yi-Lei Zhang et al.
CANCER BIOLOGY & MEDICINE (2017)
ChAMP: updated methylation analysis pipeline for Illumina BeadChips
Yuan Tian et al.
BIOINFORMATICS (2017)
TSGene 2.0: an updated literature-based knowledgebase for tumor suppressor genes
Min Zhao et al.
NUCLEIC ACIDS RESEARCH (2016)
Epigenetic modulators as therapeutic targets in prostate cancer
Ines Graca et al.
CLINICAL EPIGENETICS (2016)
Epigenetic inactivation of the CpG demethylase TET1 as a DNA methylation feedback loop in human cancers
Lili Li et al.
SCIENTIFIC REPORTS (2016)
Transcriptional implications of intragenic DNA methylation in the oestrogen receptor alpha gene in breast cancer cells and tissues
Natalie S. Shenker et al.
BMC CANCER (2015)
CDA directs metabolism of epigenetic nucleosides revealing a therapeutic window in cancer
Melania Zauri et al.
NATURE (2015)
The hypomethylating agent Decitabine causes a paradoxical increase in 5-hydroxymethylcytosine in human leukemia cells
Basudev Chowdhury et al.
SCIENTIFIC REPORTS (2015)
Epigenetic treatment of solid tumours: a review of clinical trials
Clara Nervi et al.
CLINICAL EPIGENETICS (2015)
Epigenetic Therapy for Solid Tumors: Highlighting the Impact of Tumor Hypoxia
Shaliny Ramachandran et al.
GENES (2015)
HTSeq-a Python framework to work with high-throughput sequencing data
Simon Anders et al.
BIOINFORMATICS (2015)
Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents
Magdalena Klanova et al.
MOLECULAR CANCER (2014)
HDAC4: mechanism of regulation and biological functions
Zhengke Wang et al.
EPIGENOMICS (2014)
Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer
Fahimeh Falahi et al.
BREAST CANCER RESEARCH (2014)
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Michael I. Love et al.
GENOME BIOLOGY (2014)
STAR: ultrafast universal RNA-seq aligner
Alexander Dobin et al.
BIOINFORMATICS (2013)
Deoxycytidine kinase is overexpressed in poor outcome breast cancer and determines responsiveness to nucleoside analogs
Ernst-Jan Geutjes et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Modulation of protein expression levels and DNA methylation status of breast cancer metastasis genes by anthracycline-based chemotherapy and the demethylating agent decitabine
Ferda Ari et al.
CELL BIOCHEMISTRY AND FUNCTION (2011)
Azacytidine and Decitabine Induce Gene-Specific and Non-Random DNA Demethylation in Human Cancer Cell Lines
Sabine Hagemann et al.
PLOS ONE (2011)
Mechanisms of Resistance to Decitabine in the Myelodysplastic Syndrome
Taichun Qin et al.
PLOS ONE (2011)
Altered DNA methylation is associated with docetaxel resistance in human breast cancer cells
Lena Kastl et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2010)
Demethylating agent 5-aza-2-deoxycytidine enhances susceptibility of breast cancer cells to anticancer agents
Sameer Mirza et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2010)
Valproic acid restores ERα and antiestrogen sensitivity to ERα-negative breast cancer cells
N. Fortunati et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2010)
Targeting DNA methylation for epigenetic therapy
Xiaojing Yang et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2010)
Mechanisms of resistance to 5-aza-2′-deoxycytidine in human cancer cell lines
Taichun Qin et al.
BLOOD (2009)
Epigenetic alterations in the breast: Implications for breast cancer detection, prognosis and treatment
Amy M. Dworkin et al.
SEMINARS IN CANCER BIOLOGY (2009)
Adjusting batch effects in microarray expression data using empirical Bayes methods
W. Evan Johnson et al.
BIOSTATISTICS (2007)
The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor α-negative breast cancer cells to tamoxifen
ER Jang et al.
ONCOGENE (2004)
Relative expression software tool (REST©) for group-wise comparison and statistical analysis of relative expression results in real-time PCR -: art. no. e36
MW Pfaffl et al.
NUCLEIC ACIDS RESEARCH (2002)
Adjuvant therapy for breast cancer: who should get what?
HK Chew
WESTERN JOURNAL OF MEDICINE (2001)
Share Paper
